Cytokine pathways and joint inflamation in rheumatoid arthritis

New England Journal of Medicine

Volumn 344, Issue 12, 2001, Pages 907-916

  Choy, Ernest H S ^a,b   Panayi, Gabriel S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; CYTOKINE PRODUCTION; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; RECEPTORS, CYTOKINE; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 0035932519     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103223441207     Document Type: Review

References (79)

1. Long-term outcome of treating rheumatoid arthritis: Results after 20 years
2. Taking mortality, in rheumatoid arthritis seriously - Predictive markers, socioeconomic status and comorbidity
3. An assessment of the annual and long-term direct costs: The impact of poor function and functional decline
4. The cost of rheumatoid arthritis
5. The HLA association with rheumatoid arthritis
6. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
7. The immunologic homunculus in rheumatoid arthritis
8. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
9. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
10. Cytokines in rheumatoid arthritis
11. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
12. Peripheral blood and synovial fluid monocyte expression of interleukin 1αand 1β during active rheumatoid arthritis
13. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells
14. Interleukin-11: A new cytokine critical for osteoclast development
15. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
16. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor
17. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1
18. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: Comparison of monoclonal anti TNF-α antibody with interleukin-1 receptor antagonist
19. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α
20. Role of cytokines in inflammatory synovitis: The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts
21. Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: Routes and intermediate signals
22. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
23. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
24. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
25. Cytokines in rheumatoid arthritis
26. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily
27. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types
28. Interleukin 1 signaling occurs exclusively via the type I receptor
29. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4
30. The interleukin-1 family: 10 years of discovery
31. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type receptors
32. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint
33. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra
34. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
35. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression
36. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10
37. Interleukin-6: An overview
38. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4
39. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells
40. Pro- and anti-inflammatory cytokines in rheumatoid arthritis
41. Immunoregulatory role of interleukin 10 in rheumatoid arthritis
42. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4
43. Cartilage degradation by polymorphonuclear leucocytes: In vitro assessment of the pathogenic mechanisms
44. Mechanisms of disruption of the articular cartilage surface in inflammation: Neutrophil elastase increases availability of collagen type II epitopes for binding with antibody on the surface of articular cartilage
45. The tumor necrosis factor ligand and receptor families
46. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies
47. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
48. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
49. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor
50. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
51. Inhibition of TNF by a TNF receptor immunoadhesin: Comparison to an anti-TNF monoclonal antibody
52. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody
53. Man-made antibodies
54. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10
55. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws
56. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with col- lagen-induced arthritis prevents cartilage destruction
57. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
58. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
59. Etanercept therapy in rheumatoid arthritis: A randomized controlled trial
60. Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (P75) in RA patients
61. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
62. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
63. Etanercept in children with polyarticular juvenile rheumatoid arthritis
64. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial)
65. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
66. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
67. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
68. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
69. Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis
70. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
71. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
72. Relationship of Genant scoring method with Larsen scoring method in randomized, double-blind, placebo controlled trial of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
73. IL·1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
74. Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro
75. Gene therapy for arthritis - Treatment of the first three patients
76. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA
77. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
78. rHUIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study
79. rHUIL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study